Antabio Highlights New Data on their Novel β‑lactam/β‑lactamase Inhibitor,...
Labège, France, April 27, 2026 — Antabio, a clinical-stage biopharmaceutical company developing novel antibacterial treatments targeting drug-resistant infections identified by WHO and CDC as critical...
View ArticleAntabio and GARDP join forces to identify potential next-generation antibiotics
Geneva/Labège, 23 March 2026. The French biotech company Antabio and the GARDP Foundation (known as GARDP) today announced a joint effort to accelerate crucial early-stage antibiotic discovery,...
View ArticleAntabio Announces First Subjects Dosed in Phase 1 Clinical Trial of...
Labège, France, May 25th 2023. Antabio SAS, a clinical stage biopharmaceutical company developing novel treatments for severe drug resistant bacterial infections, announces dosing of the first...
View ArticleAntabio Receives QIDP Designation from the U.S. FDA for the Development of...
Antabio SAS, a private biopharmaceutical company developing novel antibacterial treatments focused on drug-resistant life-threatening infections, announced today that the U.S. Food and Drug...
View ArticleAntabio is hiring a Project Manager
Antabio is a Labège, France-based biopharmaceutical company dedicated to the discovery of first-in-class small molecule compounds to treat severe infections caused by antibiotic-resistant bacterial...
View ArticleAntabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310
The positive Phase 1 data -including good tolerability and matching PK between ANT3310 and meropenem- supports further patient studies of MEM-ANT3310 Download the full press release here The post...
View ArticleAntabio Receives QIDP Designation from the U.S. FDA for the Development of...
Antabio SAS, a private biopharmaceutical company developing novel antibacterial treatments focused on drug-resistant life-threatening infections, announced today that the U.S. Food and Drug...
View ArticleAntabio is seeking a Clinical Pharmacologist
Antabio is a Labège, France-based biopharmaceutical company dedicated to the discovery of first-in-class small molecule compounds to treat severe infections caused by antibiotic-resistant bacterial...
View ArticleAntabio is seeking a Clinical Project Manager
Antabio is a Labège, France-based biopharmaceutical company dedicated to the discovery of first-in-class small molecule compounds to treat severe infections caused by antibiotic-resistant bacterial...
View ArticleANTABIO Announces Appointment of Dr. Erick Lelouche as Chairman of the Board
Antabio SAS is pleased to announce the appointment of Dr. Erick Lelouche as Chairman of the Board of Directors. Download the full press release here The post ANTABIO Announces Appointment of Dr. Erick...
View ArticleANTABIO Raises €25 million in Series B Financing
Led by the AMR Action Fund, with subscriptions from the EIC Fund and from Antabio’s historical investors, the financing will be used to support the clinical development of MEM-ANT3310 up to completion...
View ArticleAntabio is seeking a Regulatory Manager
Antabio is a Labège, France-based biopharmaceutical company dedicated to the discovery of first-in-class small molecule compounds to treat severe infections caused by antibiotic-resistant bacterial...
View ArticleAntabio Announces First Subjects Dosed in Phase 1 Clinical Trial of...
MEM-ANT3310 has the potential to become the next standard of care for life-threatening infections due to its unique coverage including carbapenem-resistant Enterobacterales and Acinetobacter baumannii....
View ArticleLaunch of ARPEGE, a French multidisciplinary consortium to fight antibiotic...
Led by Antabio, acting jointly with bioMérieux, Hospices Civils de Lyon, and Toulouse School of Economics, the four-year ARPEGE project has been funded by the French government with nearly €9 million...
View ArticleAntabio Awarded EUR 0.9 million funding from the Occitanie Region to support...
Télécharger le communiqué en version française The post Antabio Awarded EUR 0.9 million funding from the Occitanie Region to support the Preclinical Development of MEM-ANT3310, Antabio’s Novel...
View ArticleAntabio is seeking a Clinical Pharmacologist
Antabio is a Labège, France-based biopharmaceutical company dedicated to the discovery of first-in-class small molecule compounds to treat severe infections caused by antibiotic-resistant bacterial...
View ArticleAntabio Receives FDA Qualified Infectious Disease Product (QIDP) Designation...
Antabio SAS announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to Antabio’s MEM-ANT3310, a combination of meropenem...
View ArticleAntabio Awarded $4.4 Million from CARB-X for the Further Development of its...
The funding will be used to advance Antabio’s Pseudomonas Elastase Inhibitor (PEi) program up to completion of non-GLP preclinical studies. Download the full press release hereTélécharger le...
View ArticleAntabio applauds the new mechanism for reimbursement of antibiotics set up by...
Antabio applauds the new mechanism for reimbursement of antibiotics set up by CMS in the US On August 2, 2019, the US government announced several significant changes to hospital antibiotic...
View ArticleAntabio Receives QIDP Designation from the U.S. FDA for the Development of...
Antabio Receives QIDP Designation from the U.S. FDA for the Development of Its Metallo Beta-Lactamase inhibitor ANT2681 Labège, France, 21 June 2019. Antabio SAS, a private biopharmaceutical company...
View Article
/pic9814888.png)
/fit-in/580x348/filters:format(webp)/english-betterindia/media/media_files/2026/09/17/balaghat-3-2026-09-17-18-46-40.png)